Chronic hepatitis C virus management: 2000-2005 update

被引:35
作者
Hughes, CA
Shafran, SD
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
[2] Univ Alberta, Dept Med, Div Infect Dis, Edmonton, AB T6G 2N8, Canada
关键词
antiviral therapy; hepatitis C; interferon; pegylated interferon; ribavirin;
D O I
10.1345/aph.1G263
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To review recent advances that have significantly changed the management of chronic hepatitis C virus (HCV) infection. DATA SOURCES: A MEDLINE search (2000-July 2005) was conducted using key words such as hepatitis C, interferon, pegylated interferon, and therapy. STUDY SELECTION AND DATA EXTRACTION: All articles pertaining to treatment of chronic HCV infection were identified, Studies evaluating HCV treatment in treatment-naive patients were considered for this review. DATA SYNTHESIS: Over the past several years, response to treatment for chronic HCV infection has significantly improved with the use of pegylated interferon and ribavirin therapy. Treatment response is influenced by HCV genotype and viral load, as well as patient-related factors, including adherence. CONCLUSIONS: Treatment of chronic HCV infection has improved, with overall response rates of approximately 55%. Identification and management of common adverse effects is important in maximizing adherence and response to therapy. Studies are needed to further delineate the optimum treatment of chronic HCV infection in specific patient populations.
引用
收藏
页码:74 / 82
页数:9
相关论文
共 64 条
[31]  
LEVENSON JL, 1993, AM J GASTROENTEROL, V88, P760
[32]   A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C [J].
Lindsay, KL ;
Trepo, C ;
Heintges, T ;
Shiffman, ML ;
Gordon, SC ;
Hoefs, JC ;
Schiff, ER ;
Goodman, ZD ;
Laughlin, M ;
Yao, RJ ;
Albrecht, JK .
HEPATOLOGY, 2001, 34 (02) :395-403
[33]   Pegylated interferons for the treatment of chronic hepatitis C infection [J].
Luxon, BA ;
Grace, M ;
Brassard, D ;
Bordens, R .
CLINICAL THERAPEUTICS, 2002, 24 (09) :1363-1383
[34]   Bupropion for treatment of interferon-induced depression [J].
Malek-Ahmadi, P ;
Ghandour, E .
ANNALS OF PHARMACOTHERAPY, 2004, 38 (7-8) :1202-1205
[35]   Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 [J].
Mangia, A ;
Santoro, R ;
Minerva, N ;
Ricci, GL ;
Carretta, V ;
Persico, M ;
Vinelli, F ;
Scotto, G ;
Bacca, D ;
Annese, M ;
Romano, M ;
Zechini, F ;
Sogari, F ;
Spirito, F ;
Andriulli, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (25) :2609-2617
[36]   Adherence to combination therapy: influence on sustained virologic response and economic impact [J].
Manns, MP .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2004, 33 (01) :S11-+
[37]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965
[38]   The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C [J].
McHutchison, JG ;
Poynard, T ;
Pianko, S ;
Gordon, SC ;
Reid, AE ;
Dienstag, J ;
Morgan, T ;
Yao, RJ ;
Albrecht, J .
GASTROENTEROLOGY, 2000, 119 (05) :1317-1323
[39]   Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].
McHutchison, JG ;
Gordon, SC ;
Schiff, ER ;
Shiffman, ML ;
Lee, WM ;
Rustgi, VK ;
Goodman, ZD ;
Ling, MH ;
Cort, S ;
Albrecht, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1485-1492
[40]   Adherence to combination therapy enhances sustained response in genotyp-1-infected patients with chronic hepatitis C [J].
McHutchison, JG ;
Manns, M ;
Patel, K ;
Poynard, T ;
Lindsay, KL ;
Trepo, C ;
Dienstag, J ;
Lee, WM ;
Mak, C ;
Garaud, JJ ;
Albrecht, JK .
GASTROENTEROLOGY, 2002, 123 (04) :1061-1069